University of Karolinska and other Nordic researchers reveal that more than a third of patients with symptomatic indolent lymphoma required no chemotherapy during more than 10 years of follow-up after initial treatment with Roche’s (rituximab (Rituxan).

Lead Research/Investigator

Sandra Lockmer, MD, of Karolinska University

Source: Medpage Today

Pin It on Pinterest